Novartis AG ADR (NVS)vsQuidel Corporation (QDEL)
NVS
Novartis AG ADR
$140.98
+0.21%
HEALTHCARE · Cap: $260.70B
QDEL
Quidel Corporation
$10.94
+0.74%
HEALTHCARE · Cap: $866.79M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 2020% more annual revenue ($56.69B vs $2.67B). NVS leads profitability with a 22.5% profit margin vs -39.2%. QDEL appears more attractively valued with a PEG of 2.06. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
QDEL
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.3%
Fair Value
$93.40
Current Price
$140.98
$47.58 premium
Margin of Safety
+87.9%
Fair Value
$238.33
Current Price
$10.94
$227.39 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
2.8% revenue growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : QDEL
The strongest argument for QDEL centers on Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : QDEL
The primary concerns for QDEL are PEG Ratio, Revenue Growth, Market Cap. Debt-to-equity of 1.73 is elevated, increasing financial risk.
Key Dynamics to Monitor
NVS profiles as a value stock while QDEL is a turnaround play — different risk/reward profiles.
QDEL carries more volatility with a beta of 0.68 — expect wider price swings.
QDEL is growing revenue faster at 2.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 42/100), backed by strong 22.5% margins. QDEL offers better value entry with a 87.9% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Quidel Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for infectious disease, cardiology, thyroid, general and women's health, eye health, gastrointestinal disease, and toxicology applications globally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?